Premium
Antagomir‐155 Attenuates Acute Cardiac Rejection Using Ultrasound Targeted Microbubbles Destruction
Author(s) -
Yi Luyang,
Chen Yihan,
Jin Qiaofeng,
Deng Cheng,
Wu Ya,
Li Huiling,
Liu Tianshu,
Li Yuman,
Yang Yali,
Wang Jing,
Lv Qing,
Zhang Li,
Xie Mingxing
Publication year - 2020
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.202000189
Subject(s) - antagomir , microbubbles , medicine , microrna , cancer research , ripk1 , inflammation , ultrasound , necroptosis , radiology , apoptosis , programmed cell death , gene , chemistry , biochemistry
Abstract Antagomir‐155 is an artificial inhibitor of miRNA‐155, which is expected to be a promising therapeutic target to attenuate acute cardiac rejection (ACR). However, its vulnerability of being degraded by endogenous nuclease and potential off‐target effect make the authors seek for a more suitable way to delivery it. In attribution of efficiency and safety, ultrasound targeted microbubbles destruction (UTMD) turns out to be an appropriate method to deliver gene to target tissues. Here, cationic microbubbles to deliver antagomir‐155 downregulating miRNA‐155 in murine allograft hearts triggered by UTMD are synthesized. The viability of this therapy is verified by fluorescent microscopy. The biodistribution of antagomir‐155 is analyzed by optical imaging system. The results show antagomir‐155 delivered by UTMD which significantly decreases the levels of miR‐155. Also, this therapy downregulates the expression of cytokines and inflammation infiltration. And allograft survival time is significantly prolonged. Therefore, antagomir‐loaded microbubbles trigged by UTMD may provide a novel platform for ACR target treatment.